近期科技领域最热门的话题之一，非机器人莫属。10月21日—23日，国际智能机器人与系统大会在 浙江杭州举行。不久前，2025世界机器人大会、2025世界人形机器人运动会相继举办，一众机器人以各 自的拿手绝活吸引着大众的目光。 餐厅中，机器人大厨熟练地烹饪着自己的拿手好菜；田间地头，采摘机器人伸长手臂采摘水果；养 老院里，按摩机器人帮助老人放松筋骨……这些并非科幻电影中的桥段，而是机器人在现实世界中落地 应用的真实场景。走下展台、走出赛场，机器人如今正以超出想象的速度在各类细分场景中应用普及， 深刻改变着人们的生产生活方式。 杨福增介绍，该场景采用的机器人"眼睛看得准，手脚协同还够得着"。为了适应复杂的田间环境， 团队优化改进技术，在顺光、逆光等多变光照条件下建立精准视觉模型，通过算法迭代让机器人在各种 光照条件下都能"看清"果实。 未来，团队还将打造两款更具针对性的"娃娃型"机器人，用于苹果采摘场景：小娃负责采摘低处果 实、大娃专攻高处果实，充分照顾果树不同高度的采摘需求。 除了采摘，授粉也是农业生产必不可少的一环。 北京橡鹿科技有限公司机器人总裁办总监李朝阳介绍，这款炒菜机器人炒制的美味，覆盖八大菜 系、不 ...

在费用管控与子公司发展层面，公司呈现出"重点投入、效益提升"的特点。尽管销售费用因电商业务拓 展有所增加，但子公司经营效益显著提升，其中子公司利润增长推动应交税费较上年末增长39.38%， 反映出子公司业务规模与盈利能力的双重提升。 整体来看，药易购将继续延续医药流通优势，深化供应链优势，加快非药生产线建设与新投资项目落 地，同时持续推进创新业务拓展，以多元化业务布局与精细化运营，推动公司实现更高质量的发展，为 行业与投资者创造更大价值。 在业务布局与产业链优化方面，公司多项举措成效初显。供应链管理能力持续增强，报告期内应付账款 较上年末增长81.37%，进一步优化资金使用效率，深化与上游供应商的合作黏性，为保障药品供应稳 定性与成本控制提供有力支撑。同时，根据报告数据分析，药易购积极推进产能建设，在建工程较上年 末大幅增长360.77%，新增非药生产线工程的推进，将进一步丰富公司产品品类，拓展非药业务增长 点，助力业务结构多元化发展。 投资领域的布局也为公司注入新活力。报告期内，公司长期股权投资较上年末增长112.16%，新增对联 营企业伟哥(海南)健康产业有限公司、湖州市见素易购医药科技有限公司的投资，此 ...

Core Viewpoint - The financial performance of YaoYigou (药易购) for the first three quarters of 2025 shows a slight increase in revenue but significant losses in net profit and cash flow, indicating potential challenges in operational efficiency and profitability [1][2]. Financial Performance Summary - For the first nine months of 2025, the company achieved a revenue of 3.242 billion yuan, representing a year-on-year growth of 0.21% [1][2]. - The net profit attributable to shareholders was -8.36 million yuan, a decline of 159.98% compared to the same period last year, which reported a profit of 13.93 million yuan [1][2]. - The net profit after excluding non-recurring items was -10.15 million yuan, down 208.41% from the previous year's profit of 9.37 million yuan [1][2]. - The net cash flow from operating activities was -114.16 million yuan, a significant decrease of 397.91% compared to the previous year's cash flow of 38.32 million yuan [1][2]. Initial Public Offering (IPO) Details - YaoYigou was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 27, 2021, with an issuance of 23.92 million shares at a price of 12.25 yuan per share, raising a total of 293 million yuan [3]. - The net amount raised after deducting issuance costs was 249 million yuan, which was 196 million yuan less than the original plan of 445 million yuan [3]. Previous Year Comparison - In 2024, the company reported a revenue of 4.381 billion yuan, a decrease of 1.12% year-on-year [4]. - The net profit attributable to shareholders for 2024 was 16.36 million yuan, down 72.52% from the previous year [4]. - The net profit after excluding non-recurring items was 12.37 million yuan, a decline of 77.10% compared to the previous year [4]. - The net cash flow from operating activities for 2024 was 128 million yuan, an increase of 210.58% year-on-year [4].

Core Insights - The company reported a revenue of 1.085 billion yuan for Q3 2025, reflecting a year-on-year growth of 7.41% [1] - The net profit for the same period was a loss of 742,100 yuan, marking a significant decline of 140.42% compared to the previous year [1] Financial Performance - Q3 2025 revenue: 1.085 billion yuan, up 7.41% year-on-year [1] - Q3 2025 net profit: -742,100 yuan, down 140.42% year-on-year [1]

Core Viewpoint - The company reported a year-on-year increase in revenue for Q3 2025, but net profit remains negative, indicating potential challenges in profitability despite revenue growth [1] Financial Performance - The company's operating revenue for Q3 2025 was 1.085 billion, representing a year-on-year increase of 7.41% [1] - The net profit attributable to shareholders was -742,100, indicating a loss [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -1.8295 million, further highlighting profitability issues [1]

Core Insights - The company reported a revenue of 3.242 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 0.21%, while the net profit attributable to shareholders was -8.3565 million yuan, a decline of 159.98% [1] - In Q3 alone, the company achieved a revenue of 1.085 billion yuan, marking a year-on-year increase of 7.41% [1] Financial Performance - The revenue performance for the first three quarters was stable, but the profit was under short-term pressure due to significant impacts from income tax expenses and goodwill impairment [1] - The increase in income tax expenses was primarily due to profit increases in some subsidiaries and changes in business models, leading to the reversal of previously recognized deferred tax assets [1] - Goodwill impairment was noted in the subsidiary Jingcheng Mingyi, prompting a goodwill impairment test at the end of the period [1] - Sales expenses increased by 42.47% year-on-year, driven by rapid growth in the e-commerce business and increased online promotion expenditures while maintaining controllable profits [1] Strategic Initiatives - The company is actively pursuing strategic transformation, focusing on the outpatient market to seek breakthroughs amid industry policy and market competition challenges [2] - Despite short-term profit pressures, the company has made significant progress in strategic transformation and ecological layout [2] - The digital empowerment platform (such as Yaojuli) and the C-end full-domain reach network are gradually building competitive barriers in the industry [2] - Continuous investment in innovative fields through industrial funds and data asset operations is aimed at long-term growth [2] - The company is expected to gain a competitive edge in the outpatient market's full-chain services as the ecological closed loop accelerates and the proportion of high-margin businesses increases [2]

（记者 王晓波） 截至发稿，药易购市值为27亿元。 每经AI快讯，药易购（SZ 300937，收盘价：27.83元）10月23日晚间发布三季度业绩公告称，2025年前 三季度营收约32.42亿元，同比增加0.21%；归属于上市公司股东的净利润亏损约836万元；基本每股收 益亏损0.09元。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ ...

Group 1 - The core point of the article is that Yaoyigou (SZ 300937) held its third meeting of the fourth board of directors on October 23, 2025, via telecommunication voting, discussing the proposal to amend certain company systems [1] - For the first half of 2025, Yaoyigou's revenue composition was as follows: pharmaceutical distribution (contract distribution + market comparison) accounted for 47.09%, pharmaceutical sales (direct procurement) accounted for 41.92%, pharmaceutical manufacturing and OEM business accounted for 8.55%, and other businesses accounted for 2.44% [1] - As of the time of reporting, Yaoyigou's market capitalization was 2.7 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year, highlighting the hot secondary market in biomedicine while questioning the cold fundraising environment in the primary market [1]

四川合纵药易购医药股份有限公司 信息披露管理制度 第一章 总 则 第一条 为规范和加强四川合纵药易购医药股份有限公司（以下简称"公司"） 信息披露事务管理，提高信息披露管理水平和质量，切实维护公司和股东的合法 权益，根据《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司信息披露管理办法》《上市公司信息披露暂缓与豁免管理 规定》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律 监管指引第 5 号——信息披露事务管理》等有关法律、法规规定以及《四川合纵 药易购医药股份有限公司章程》（以下简称"公司章程"），特制定本制度。 第二条 本制度所称"信息"特指中国证券监督管理委员会（以下简称"中 国证监会"）、证券交易所要求披露的信息和将可能对公司生产经营产生重大影 响而尚未公布的反映公司情况的信息。 本制度所称"披露"系指以规定的时间、媒体及方式向社会公众公布前述信 息以及按规定报送中国证监会、证券交易所的行为。 第三条 本制度中所称"信息披露义务人"，系指公司及其董事、高级管理 人员、股东、 ...

四川合纵药易购医药股份有限公司 投资者关系管理制度 第一章 总则 第一条 为规范四川合纵药易购医药股份有限公司（以下简称"公司"）投 资者关系管理工作，加强公司与投资者之间的沟通，保护投资者合法权益，提升 公司治理水平和企业整体价值，根据《中华人民共和国公司法》《上市公司投资 者关系管理工作指引》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律、法规规定及《四川合纵药易购医药股份有限 公司章程》（以下简称"公司章程"），特制定本制度。 第二条 本制度所称的投资者关系管理，是指公司通过便利股东权利行使、 信息披露、互动交流和诉求处理等工作，加强与投资者及潜在投资者（以下简称 "各类投资者"）之间的沟通，增进各类投资者对公司的了解和认同，以提升公 司治理水平和整体价值，实现尊重投资者、回报投资者、保护投资者目的的相关 活动。 第二章 原则及职责 第三条 公司开展投资者关系管理工作应当遵循以下基本原则： （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律法规、规章及规范性文件、行业规范和自律规则、公司内部 规章制度，以及行业普遍遵守的道德规范 ...